Examination of the Effects of Chromium Levels on Glucose Metabolism, Lipid Metabolism, Morbidity and Mortality Rates in Patients Followed in Intensive Care Unit

NCT06334042 | Completed Results

• 1 other identifier: GO 23/488
• Study Type: observational
• Target: 309
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to determine the effects of chromium serum levels on glucose metabolism, lipid metabolism, morbidity and mortality rates in critically ill intensive care patients. The investigators' goal is to provide a different perspective on solving the common problems of hyperglycemia and dyslipidemia encountered in intensive care patients, aiming to reduce morbidity and mortality rates. Participants will give a single blood sample (into trace element serum sample tube) on the day of admission to the intensive care unit, along with routine blood tests, and samples will be taken once a week during their stay in the intensive care unit.

Conditions

Chromium Deficiency; Diabetes Mellitus; Hyperlipidemias; Hypercholesterolemia

Keywords

Intensive care; Metabolism,glucose; Metabolism,lipid

Outcome Measures

Primary Outcomes (1)

• Serum Chromium Level

  Serum chromium levels of participants were measured once a week throughout the participant's ICU stay, starting from admission. The healthy reference range of 0.7 to 28.0 µg/L for blood chromium levels was used.

  Once a week throughout the participant's ICU stay, starting from admission (day 0, day 7, day 14 and day 21).

Secondary Outcomes (4)

• HbA1c

  At the time of ICU admission (day 0).

• Blood Glucose

  Week 1, week 2, week 3 and week 4.

• Lipid Profile

  Once a week throughout the participant's ICU stay, starting from admission (day 0, day 7, day 14 and day 21).

• Glycemic Variability - Coefficient of Variation (CV)

  During each participant's ICU stay (ranging from 1 to 4 weeks).

Study Arms (1)

Intensive Care Patients

Diagnostic Test: Serum Chromium Level

Interventions

Serum Chromium Level DIAGNOSTIC_TEST

Measuring serum chromium levels from patients who admitted in intensive care unit.

Intensive Care Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Every patient; who is over/and 18 years old age, admitted to Anesthesiology Intensive Care Unit, agreed to participate in the study (with informed consent) and not - taking chromium supplement

You may qualify if:

• Age ≥ 18 years old
• Admitted to Anesthesiology Intensive Care Unit

You may not qualify if:

• Patient Refusal
• Taking Chromium Supplement

Sponsors & Collaborators

• Oguzhan Kahveci: lead

Study Sites (1)

Hacettepe University

Ankara, 06230, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Diabetes Mellitus; Hyperlipidemias; Hypercholesterolemia

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Dyslipidemias; Lipid Metabolism Disorders

Results Point of Contact

• Title: Oguzhan Kahveci, MD
• Organization: Hacettepe University Department of Anesthesiology and Intensive Care

kahveci.oguz@hotmail.com

+903123051207

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Anesthesiology Resident, MD

Study Record Dates

• First Submitted: March 12, 2024
• First Posted: March 27, 2024
• Study Start: February 7, 2024
• Primary Completion: August 8, 2024
• Study Completion: August 14, 2024
• Last Updated: April 13, 2025
• Results First Posted: April 13, 2025

Record last verified: 2025-04

Locations

TU (1)